2026-05-25T15:31:58Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/2455-5460.000016 2017-05-26 PTZ.ADA:VOL3

Bupropion Sustained released versus Placebo for seasonal affective Disorder Martin H Teicher Danielle M WebsterSteven B Lowen<p><strong>Background</strong>: The majority of seasonal affective disorder&nbsp; (SAD) studies have evaluated&nbsp; the&nbsp; use of &nbsp; light or selective serotonin reuptake inhibitors (SSRI). The purpose of the present study was to evaluate bupropion sustained-released (SR), a non-SSRI antidepressant, for the treatment of SAD.</p><p><strong>Method</strong>:&nbsp; Forty-one adults meeting DSM IV criteria for SAD were recruited into a six-week, randomized, double-blind,&nbsp; placebo-controlled trial. Participants started on bupropion&nbsp; SR&nbsp; 150&nbsp; mg&nbsp; QD&nbsp; (or&nbsp; equivalent placebo&nbsp; pills)&nbsp; and&nbsp; titrated&nbsp; up&nbsp; to&nbsp; 200&nbsp; mg BID&nbsp; if&nbsp; tolerated&nbsp; by&nbsp; week 4. Participants&nbsp; were&nbsp; evaluated weekly with SIGH-SAD and self-reported Kellner Symptom Questionnaire (SQ). Mixed effects growth models and receiver operating characteristic (ROC) analyses were used to compare treatments.</p><p><strong>Results </strong>: Analysis was done on the 36 participants who completed at least 2 weeks of treatment, as per protocol. Thirty-four participants&nbsp; completed the entire&nbsp; protocol; two&nbsp; participants receiving placebo dropped&nbsp; out&nbsp; during&nbsp; weeks 3 and 5. Sixteen&nbsp; participants&nbsp; (7 male, 9 female, 46.5&nbsp; +&nbsp; 9.6&nbsp; years, mean+SD) received bupropion SR and 20 participants&nbsp; (8 males, 12 females,&nbsp; 48.2+8.8&nbsp; years)&nbsp; received&nbsp; placebo.&nbsp; Participants&nbsp; receiving&nbsp; bupropion&nbsp; SR had a more rapid reduction&nbsp; in&nbsp; atypical&nbsp; SIGH-SAD&nbsp; depressive&nbsp; symptoms and lower depression scores across time on the SQ. ROC&nbsp; analyses&nbsp; revealed&nbsp; that&nbsp; positive effects of bupropion SR on total SIGH-SAD scores were more evident in males than females. Bupropion SR was well tolerated. </p><p><strong>Conclusion </strong>: Bupropion SR may be beneficial for the treatment of SAD, but larger randomized placebo- controlled studies are warranted</p> Archives of Depression and Anxiety - Peertechz Publications 2017-05-26 Research Article https://doi.org/10.17352/2455-5460.000016 en Copyright © Martin H Teicher et al.